ValuEngine upgraded shares of Zafgen, Inc. (NASDAQ:ZFGN) from a strong sell rating to a sell rating in a report issued on Monday.
Separately, Zacks Investment Research lowered shares of Zafgen from a buy rating to a hold rating in a research report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $6.38.
Shares of Zafgen (NASDAQ ZFGN) opened at 3.74 on Monday. The stock’s market capitalization is $102.79 million. Zafgen has a one year low of $2.89 and a one year high of $5.46. The company’s 50-day moving average is $3.51 and its 200-day moving average is $3.84.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the previous year, the business earned ($0.55) earnings per share. On average, equities research analysts anticipate that Zafgen will post ($2.23) earnings per share for the current year.
In other news, Director Frances K. Heller acquired 10,000 shares of the stock in a transaction that occurred on Friday, October 13th. The shares were purchased at an average cost of $3.90 per share, for a total transaction of $39,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 21.20% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Algert Global LLC purchased a new position in Zafgen in the 2nd quarter valued at $123,000. Parametric Portfolio Associates LLC grew its position in Zafgen by 55.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 10,327 shares during the last quarter. Wells Fargo & Company MN grew its position in Zafgen by 1,290.3% in the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 40,400 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at $259,000. Finally, LMR Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at $299,000. Hedge funds and other institutional investors own 48.52% of the company’s stock.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.